Medicine and Dentistry
Acute Graft Versus Host Disease
100%
Interleukin 1
100%
Allogenic Bone Marrow Transplantation
100%
Interleukin 1 Receptor Blocking Agent
100%
Placebo
100%
Graft Versus Host Reaction
100%
Stem Cell
16%
T Cell
16%
Clinical Trial
16%
Whole Body Radiation
16%
Randomized Controlled Trial
16%
Prophylaxis
16%
Allogeneic Stem Cell Transplantation
16%
Cyclophosphamide
16%
Cyclosporine
16%
T Cell Activation
16%
Cell Damage
16%
Conditioning
16%
Tumor Necrosis Factor
16%
Perforin
16%
Overall Survival
16%
Target Tissue
16%
Inflammatory Mediator
16%
Event Free Survival
16%
Inflammatory Cytokine
16%
Methotrexate
16%
Interferon
16%
Histocompatibility
16%
Granzyme
16%
Keyphrases
Randomized Placebo-controlled Trial
100%
Graft-versus-host Disease (GvHD)
100%
Allogeneic Bone Marrow Transplantation
100%
Interleukin-1 Receptor Antagonist (IL-1Ra)
100%
IL-1 Blockade
100%
Interleukin-1β
37%
Placebo
25%
Transplantation
25%
Clinical Trials
12%
FasL
12%
Moderate to Severe
12%
Inflammatory Cytokines
12%
T Cells
12%
Disease Risk
12%
Recombinant Human
12%
Cyclosporine
12%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
12%
Placebo-controlled Randomized Trial
12%
Cyclophosphamide
12%
T Cell Activation
12%
Interferon-α (IFN-α)
12%
Cell Injury
12%
Total Body Irradiation
12%
Disease Prevention
12%
Methotrexate
12%
Inflammatory Mediators
12%
Event-free Survival
12%
Overall Survival
12%
Perforin
12%
Tumor Necrosis Factor-α
12%
Stem Cell Source
12%
Hematologic Recovery
12%
Granzyme
12%
Histocompatibility
12%
Host Toxicity
12%
Immunology and Microbiology
Graft-Versus-Host Disease
100%
Acute Graft Versus Host Disease
100%
Interleukin 1
100%
Allogeneic Bone Marrow Transplantation
100%
Interleukin 1 Receptor Antagonist
100%
Interferon Type I
16%
Tumor Necrosis Factor
16%
T Cell Activation
16%
Histocompatibility
16%
Inflammatory Cytokine
16%
Ciclosporin
16%
Stem Cell
16%
Mediator
16%
Allogeneic Stem Cell Transplantation
16%
Methotrexate
16%
Conditioning
16%
Perforin
16%
Overall Survival
16%
Event Free Survival
16%
Target Tissue
16%
T Cell
16%
Cell Damage
16%
Cyclophosphamide
16%
Granzyme
16%
Pharmacology, Toxicology and Pharmaceutical Science
Graft Versus Host Reaction
100%
Placebo
100%
Acute Graft Versus Host Disease
100%
Interleukin 1
100%
Interleukin 1 Receptor Blocking Agent
100%
Clinical Trial
16%
Randomized Controlled Trial
16%
Tumor Necrosis Factor
16%
Ciclosporin
16%
Injury
16%
Methotrexate
16%
Cyclophosphamide
16%
Cytokine
16%
Event Free Survival
16%
Overall Survival
16%
Perforin
16%
Interferon
16%
Granzyme
16%
Neuroscience
Interleukin 1 Receptor Antagonist
100%
Interleukin 1
100%
Placebo
100%
Stem Cell
50%
T Cell
50%
Randomized Controlled Trial
25%
Ciclosporin
25%
Cyclophosphamide
25%
Interferon
25%
Methotrexate
25%
Granzyme
25%
Cell Activation
25%
Perforin
25%
Cell Damage
25%
Necrosis
25%
Agricultural and Biological Sciences
Graft Versus Host Reaction
100%
Bone Marrow
100%
Interleukin 1 Receptor Antagonist
100%
Placebo
100%
Interleukin-1
100%
T Cell
25%
Perforin
12%
Tumor Necrosis Factor
12%
Cytokine
12%
Progenitor Cell
12%
Cell Damage
12%
Histocompatibility
12%
Stem Cell Therapy
12%
Granzyme
12%
Ciclosporin
12%
Pretreatment
12%